Detalhe da pesquisa
1.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37340869
2.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130806
3.
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
HIV Med
; 24(2): 202-211, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35945163
4.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33308425
5.
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Br J Clin Pharmacol
; 88(10): 4607-4622, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35695476
6.
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Liver Int
; 34(6): e89-95, 2014 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-24107072
7.
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project.
Clin Pharmacol Ther
; 114(1): 29-40, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36550769
8.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Lancet HIV
; 8(11): e668-e678, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34656207
9.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS
; 35(9): 1333-1342, 2021 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33730748
10.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33794181
11.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33136751
12.
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
PLoS One
; 14(11): e0225199, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31725787
13.
HIV prevention trial design in an era of effective pre-exposure prophylaxis.
HIV Clin Trials
; 18(5-6): 177-188, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-29039265
14.
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Antivir Ther
; 7(1): 43-51, 2002 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-12008787
15.
Abacavir and the potential risk of myocardial infarction.
Lancet
; 371(9622): 1413, 2008 Apr 26.
Artigo
Inglês
| MEDLINE | ID: mdl-18387668
16.
Risk factor analysis of hypersensitivity reactions to abacavir.
Clin Ther
; 24(4): 565-73, 2002 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-12017401
17.
Statistics 101. A basic guide to the numbers game behind research.
Posit Aware
; 19(6): 55-8, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-19062411
18.
Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
J Acquir Immune Defic Syndr
; 51(1): 20-8, 2009 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-19282778
19.
Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir.
Ann Pharmacother
; 38(12): 2171-2, 2004 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-15536137